Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Oberst

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Cell Chemical Biology|March 12, 2021
HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cellsLeiming Xia, Lu Wen, You Qin, et al.
Molecular Cancer Therapeutics|March 17, 2018
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion ProteinMichael D Oberst, Catherine Augé, Chad Morris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2017
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 AgonistRebecca Leyland, Amanda Watkins, Kathy A Mulgrew, et al.
Cancer Discovery|July 7, 2021
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 KnockdownNabendu Pore, Song Wu, Nathan Standifer, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Cell Chemical Biology|March 12, 2021
HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cellsLeiming Xia, Lu Wen, You Qin, et al.
Molecular Cancer Therapeutics|March 17, 2018
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion ProteinMichael D Oberst, Catherine Augé, Chad Morris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2017
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 AgonistRebecca Leyland, Amanda Watkins, Kathy A Mulgrew, et al.
Cancer Discovery|July 7, 2021
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 KnockdownNabendu Pore, Song Wu, Nathan Standifer, et al.
Pageof 2